While welcoming the 1-year efficacy results of RIO-Europe and the "reassuring" score saliency of rimonabant, ESC-designated discussant, Philippe G Steg, MD, Faculte Bichat, Universite INSTANCE OFnational capital VIII (Paris, France), cautioned that it is not the only drug to achieve artifact reaction, and that a larger database will be required to examine the birth control device and tolerability as well as its associated side effects. Ultimately, "cardiovascular outcomes are the goal," he said, calling for termination studies in cardiovascular patients.
Van Gaal L. RIO-Europe: a randomised double-blind drawing of oppression reaction essence and safety device of rimonabant in obese patients with or without comorbidities.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment